Point design targets have been specified for the initial ignition campaign on the National Ignition Facility [G. H. Miller, E. I. Moses, and C. R. Wuest, Opt. Eng. 443, 2841 (2004)]. The targets contain D-T fusion fuel in an ablator of either CH with Ge doping, or Be with Cu. These shells are imploded in a U or Au hohlraum with a peak radiation temperature set between 270 and 300 eV. Considerations determining the point design include laser-plasma interactions, hydrodynamic instabilities, laser operations, and target fabrication. Simulations were used to evaluate choices, and to define requirements and specifications. Simulation techniques and their experimental validation are summarized. Simulations were used to estimate the sensitivity of target performance to uncertainties and variations in experimental conditions. A formalism is described that evaluates margin for ignition, summarized in a parameter the Ignition Threshold Factor (ITF). Uncertainty and shot-to-shot variability in ITF are evaluated, and sensitivity of the margin to characteristics of the experiment. The formalism is used to estimate probability of ignition. The ignition experiment will be preceded with an experimental campaign that determines features of the design that cannot be defined with simulations alone. The requirements for this campaign are summarized. Requirements are summarized for the laser and target fabrication.
Presenilins are integral membrane protein involved in the production of amyloid -protein. Mutations of the presenilin-1 and -2 gene are associated with familial Alzheimer's disease and are thought to alter ␥-secretase cleavage of the -amyloid precursor protein, leading to increased production of longer and more amyloidogenic forms of A, the 4-kDa -peptide. Here, we show that radiolabeled ␥-secretase inhibitors bind to mammalian cell membranes, and a benzophenone analog specifically photocross-links three major membrane polypeptides. A positive correlation is observed among these compounds for inhibition of cellular A formation, inhibition of membrane binding and cross-linking. Immunological techniques establish N-and C-terminal fragments of presenilin-1 as specifically cross-linked polypeptides. Furthermore, binding of ␥-secretase inhibitors to embryonic membranes derived from presenilin-1 knockout embryos is reduced in a gene dose-dependent manner. In addition, C-terminal fragments of presenilin-2 are specifically cross-linked. Taken together, these results indicate that potent and selective ␥-secretase inhibitors block A formation by binding to presenilin-1 and -2.-Amyloid precursor protein (APP) 1 is a transmembrane protein that undergoes processing to A by proteolytic activities known as -and ␥-secretases (for review, see Refs. 1-3). The -secretase cleavage occurs in the extracellular domain by a recently identified aspartyl protease variously termed BACE, memapsin, and Asp2 (4 -9), whereas the heterogeneous ␥-secretase cleavage occurs in the transmembrane domain (2, 10). Dominant mutations in either of the two human presenilin (PS-1 and PS-2) genes lead to familial Alzheimer's disease (AD). PS-1 and -2 are polytopic membrane proteins (for review, see Refs. 11-13). Presenilins are proteolytic processed. In vivo, only small amounts of the holoprotein can be detected, primarily in the nuclear envelope, whereas 30-kDa N-terminal and 20-kDa C-terminal fragments of presenilin are observed in all mammalian tissues and cell lines analyzed so far. Coimmunoprecipitation experiments revealed that presenilin fragments are assembled into a high molecular weight complex together with other proteins (for review see 11-13). The proposed mechanism through which the presenilin mutations cause AD is an alteration in the predominant ␥-secretase cleavage site which increases the amount of the longer, more amyloidogenic A 1-42(43) fragments produced (11-13). A null mutation of the mouse PS-1 selectively reduces ␥-secretase activity (14), and site-directed mutagenesis of PS-1 and PS-2 at two conserved aspartyl residues, which resemble the catalytic center of aspartyl proteases, also reduces ␥-secretase activity (15, 16). These observations indicate that PS-1 and PS-2 either stimulate the activity of ␥-secretase by trafficking to appropriate cellular compartments, serve as cofactors of the ␥-secretase, or are ␥-secretase themselves.Here, we report that a series of potent and selective ␥-secretase inhibitors bind to mam...
Tau is a microtubule (MT)-stabilizing protein that is altered in Alzheimer's disease (AD) and other tauopathies. It is hypothesized that the hyperphosphorylated, conformationally altered, and multimeric forms of tau lead to a disruption of MT stability; however, direct evidence is lacking in vivo. In this study, an in vivo stable isotope-mass spectrometric technique was used to measure the turnover, or dynamicity, of MTs in brains of living animals. We demonstrated an age-dependent increase in MT dynamics in two different tau transgenic mouse models, 3xTg and rTg4510. MT hyperdynamicity was dependent on tau expression, since a reduction of transgene expression with doxycycline reversed the MT changes. Treatment of rTg4510 mice with the epothilone, BMS-241027, also restored MT dynamics to baseline levels. In addition, MT stabilization with BMS-241027 had beneficial effects on Morris water maze deficits, tau pathology, and neurodegeneration. Interestingly, pathological and functional benefits of BMS-241027 were observed at doses that only partially reversed MT hyperdynamicity. Together, these data suggest that tau-mediated loss of MT stability may contribute to disease progression and that very low doses of BMS-241027 may be useful in the treatment of AD and other tauopathies.
Phosphorothioate nucleotides have emerged as powerful pharmacological substitutes of their native phosphodiester analogs with important translational applications in antisense oligonucleotide (ASO) therapeutics and cyclic dinucleotide (CDN) synthesis. Stereocontrolled installation of this chiral motif has long been hampered by the systemic use of phosphorus(III) [P(III)]-based reagent systems as the sole practical means of oligonucleotide assembly. A fundamentally different approach is described herein: the invention of a P(V)-based reagent platform for programmable, traceless, diastereoselective phosphorus-sulfur incorporation. The power of this reagent system is demonstrated through the robust and stereocontrolled synthesis of various nucleotidic architectures, including ASOs and CDNs, via an efficient, inexpensive, and operationally simple protocol.
During the course of our research efforts to develop a potent and selective γ-secretase inhibitor for the treatment of Alzheimer's disease, we investigated a series of carboxamide-substituted sulfonamides. Optimization based on potency, Notch/amyloid-β precursor protein selectivity, and brain efficacy after oral dosing led to the discovery of 4 (BMS-708163). Compound 4 is a potent inhibitor of γ-secretase (Aβ40 IC50 = 0.30 nM), demonstrating a 193-fold selectivity against Notch. Oral administration of 4 significantly reduced Aβ40 levels for sustained periods in brain, plasma, and cerebrospinal fluid in rats and dogs.
The amyloid- (A) peptide, which likely plays a key role in Alzheimer disease, is derived from the amyloid- precursor protein (APP) through consecutive proteolytic cleavages by -site APP-cleaving enzyme and ␥-secretase. Unexpectedly ␥-secretase inhibitors can increase the secretion of A peptides under some circumstances. This "A rise" phenomenon, the same inhibitor causing an increase in A at low concentrations but inhibition at higher concentrations, has been widely observed. Here we show that the A rise depends on the -secretase-derived C-terminal fragment of APP (CTF) or C99 levels with low levels causing rises. In contrast, the N-terminally truncated form of A, known as "p3," formed by ␣-secretase cleavage, did not exhibit a rise. In addition to the A rise, low CTF or C99 expression decreased ␥-secretase inhibitor potency. This "potency shift" may be explained by the relatively high enzyme to substrate ratio under conditions of low substrate because increased concentrations of inhibitor would be necessary to affect substrate turnover. Consistent with this hypothesis, ␥-secretase inhibitor radioligand occupancy studies showed that a high level of occupancy was correlated with inhibition of A under conditions of low substrate expression. The A rise was also observed in rat brain after dosing with the ␥-secretase inhibitor BMS-299897. The A rise and potency shift are therefore relevant factors in the development of ␥-secretase inhibitors and can be evaluated using appropriate choices of animal and cell culture models. Hypothetical mechanisms for the A rise, including the "incomplete processing" and endocytic models, are discussed.Evidence suggests that the amyloid- (A) 9 peptide plays a key role in Alzheimer disease. A is generated by proteolytic processing of the amyloid- precursor protein (APP) through consecutive cleavages by the -site APP-cleaving enzyme (BACE) and ␥-secretase. APP is cleaved by BACE to form a -secretase-derived C-terminal fragment of APP (CTF), which undergoes further cleavage by ␥-secretase to form A. In addition, APP is cleaved by ␣-secretase to form ␣CTF, which undergoes ␥-secretase cleavage to produce an N-terminally truncated form of A known as "p3." Using the conventional amino acid numbering of A, BACE cleavage leads to A peptides with N-terminal ends at positions 1 and 11, whereas ␣-secretase leads to p3 peptides with an N-terminal end at position 17. Cleavage of CTF and ␣CTF by ␥-secretase produces a mixture of different C termini in the resulting A and p3 peptides. For example, the predominant ␥-secretase cleavage of CTFs at position 40 produces A-(1-40) and A-(11-40), whereas other ␥-secretase cleavage sites produce a range of less abundant A peptides, such as the disease-associated A-(1-42) (1, 2).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.